Lilly's 2.2% A1C Win Puts Novo's Oral Lead at Risk

ACHIEVE-3 gave Lilly the first clean head-to-head edge

Lilly has put Novo's oral lead under real pressure.

In ACHIEVE-3, orforglipron 36 mg cut A1C by 2.2% versus 1.4% for oral semaglutide 14 mg. That is more than a marginal difference. For the first time, Lilly produced a direct head-to-head Phase 3 win against oral semaglutide in adults with type 2 diabetes, giving investors a live read on competitive positioning before obesity outcomes are fully in.

The market opportunity is large enough to matter. Goldman Sachs projects oral GLP-1s could reach about $22 billion by 2030. That makes this not just a niche oral formulation battle, but a meaningful extension of the broader GLP-1 business.

The bullish case is straightforward: Lilly is leading in direct comparison data. The cautious counterpoint is just as clear: ACHIEVE-3 was a diabetes trial, not an obesity trial, so the results still need to be validated in the population that will ultimately drive commercial success.

Convenience plus efficacy is Lilly's clearest commercial angle

Orforglipron removes a key dosing friction point

Orforglipron is being positioned as a pill that can be taken without food or water restrictions. By contrast, Wegovy's pill requires an empty stomach and a 30-minute fast before eating or drinking.

That distinction may matter more than the efficacy gap alone. For a chronic-condition treatment, simpler dosing can improve adherence because patients do not have to restructure their mornings around the drug.

The trial supports the convenience story

The patient demand for oral options is easy to understand. 63.2% of adults report experiencing some degree of needle fear, which helps explain why oral GLP-1s have such strong consumer appeal.

In ACHIEVE-3, orforglipron 36 mg also produced more weight loss than oral semaglutide 14 mg. That matters because Lilly is not asking clinicians to choose between a more convenient pill and a weaker one. At least in this trial, the easier-to-take candidate also showed better results.

Market expectations lean toward the smoother option

Goldman Sachs' outlook is even more favorable to Lilly at the share level, forecasting orforglipron could capture about 60% versus 21% for Novo's pill in the oral segment.

Rybelsus is still the clearest commercial caution. Novo showed the market wants oral GLP-1s, but dosing constraints appear to have limited how much revenue migrated from the injection format. If the same pattern repeats, Lilly does not need to win on every metric. It just needs to become the default oral option doctors can prescribe without detailed administration instructions.

Better diabetes results still are not a final verdict

The obesity read is still the real test

Bears are right on one important point: ACHIEVE-3 was conducted in adults with type 2 diabetes, not in the obesity population that will ultimately determine the commercial winner. Investors should separate "better in diabetes" from "will win in obesity."

Lilly has already signaled that the next major checkpoint is close, with obesity action expected in Q2 2026. It also plans to ask the FDA later this year for diabetes approval. Those are the next confirmation points, not the head-to-head diabetes A1C result alone.

Tolerability is the strongest bear case

The most important risk is adherence. Investigators also flagged higher rates of side effects in orforglipron recipients that led people to stop treatment. That means the central commercial question is no longer just efficacy. It is whether patients can stay on the drug long enough to realize its benefit.

There is another limitation to keep in mind. The semaglutide arm used lower doses than the established obesity dosing regimen, so this was not a perfect apples-to-apples obesity setup. Bulls can still say the efficacy signal is compelling. Bears will say it is exactly why the data still need to be tested in the right population.

What needs to happen next

Investors should treat this head-to-head win as Lilly taking the first clean lead, not as final proof. The more important signals are:

• Whether Lilly carries the efficacy advantage into obesity-specific results.
• Whether tolerability improves enough to keep discontinuation manageable.
• Whether payers adopt the convenience argument outside the trial setting.
• Whether regulatory timing stays on track for the expected obesity review window.

Q2 2026 is the next hard checkpoint

The diabetes lead is real, but the next test is simpler: can Lilly translate it into obesity success before the market loses patience?

The key date is obesity action expected in Q2 2026. That will be the first clean opportunity to see whether a win in type 2 diabetes travels into the market that will really decide the winner. Lilly also plans to ask the FDA later this year for diabetes approval, so investors will get two separate reads rather than one.

The main things that would weaken the early Lilly case are straightforward:

• Obesity timing slips past Q2 2026.
• Side effects keep discontinuation concerns elevated.
• Head-to-head obesity data show the diabetes advantage does not carry over.

If Lilly clears that window with tolerability under control, the early lead starts to look commercial rather than merely clinical.